New IgA Nephropathy Drug Sefaxersen Could Cut Proteinuria
Adults with IgA nephropathy may see a new treatment option as trial data shows reduced protein levels.
Updated on Oct. 23, 2026 in Diabetes
Live Poll
Do you trust that pharmaceutical companies prioritize patient welfare over profit when developing new medical treatments?
Roche shared phase III results showing its experimental drug sefaxersen reduced protein in the urine of adults with IgA nephropathy by 43.1% compared to a placebo. This once-monthly treatment aims to slow the progression of kidney disease, which affects 25 adults per million worldwide annually.
Why it matters
IgA nephropathy frequently leads to end-stage kidney disease in up to 50% of patients within 20 years, making new therapies that address underlying inflammation critical. This development represents a potential move toward reducing that long-term risk through targeted complement system inhibition.
In a phase III randomized trial of 459 participants, sefaxersen achieved a 43.1% reduction in proteinuria compared to placebo at 37 weeks. Long-term outcomes on kidney function are still under investigation.
The players
Roche
A global pharmaceutical company focused on diagnostics and treatments for oncology, immunology, and nephrology.
The details
Sefaxersen is a once-monthly subcutaneous injection that works by inhibiting complement factor B production in the liver. By blocking this specific component of the complement system, the drug aims to reduce inflammation within the kidneys. This reduction in the protein-to-creatinine ratio is used as a surrogate measure to predict the long-term slowing of kidney disease progression.
Timeline
October 23, 2026: Phase III study data presented at ASN Kidney Week.
37 weeks: Primary endpoint measured by reduction in proteinuria.
105 weeks: End of study blinded evaluation period.
Health Landscape
The study follows the clinical research trend of targeting the complement pathway to manage autoimmune kidney conditions. It sits within a broader landscape of efforts to prevent the high incidence of end-stage renal disease associated with chronic inflammatory nephropathies.
This finding highlights an emerging approach to managing IgA nephropathy, which is worth discussing with your nephrologist if you are navigating chronic kidney disease. Ask your specialist about the role of complement pathway inhibitors and how they might fit into long-term care plans.
The takeaway
Sefaxersen shows potential in reducing protein markers of kidney inflammation by over 40% in clinical trials. Patients concerned about kidney function should consult their physician regarding current treatment options and the significance of tracking proteinuria levels in routine care.
What happens next
The IMAgINATION study will continue until week 105 to evaluate long-term changes in estimated glomerular filtration rate.
Further reading
For more information on managing chronic kidney health, visit our Diabetes section.
More information
View the IMAgINATION study trial registry details for official study documentation.
Live Poll
Do you trust that pharmaceutical companies prioritize patient welfare over profit when developing new medical treatments?
